Endo International Stock Forecast, Price & News

Endo International (NASDAQ:ENDP) Frequently Asked Questions

Is Endo International a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International or view top-rated stocks.

How has Endo International's stock price been impacted by Coronavirus (COVID-19)?

Endo International's stock was trading at $3.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENDP shares have increased by 34.7% and is now trading at $5.24.
View which stocks have been most impacted by COVID-19.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Endo International.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) announced its earnings results on Thursday, November, 4th. The company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.46 by $0.34. The firm earned $772.03 million during the quarter, compared to analyst estimates of $667.94 million. Endo International had a negative trailing twelve-month return on equity of 108.42% and a net margin of 2.30%. The business's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 earnings per share.
View Endo International's earnings history.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided EPS guidance of $2.800-$2.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.330. The company issued revenue guidance of $2.90 billion-$2.94 billion, compared to the consensus revenue estimate of $2.79 billion.

What price target have analysts set for ENDP?

6 brokers have issued 12 month target prices for Endo International's stock. Their forecasts range from $3.00 to $11.00. On average, they expect Endo International's stock price to reach $6.60 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price.
View analysts' price targets for Endo International or view top-rated stocks among Wall Street analysts.

Who are Endo International's key executives?

Endo International's management team includes the following people:

• Blaise A Coleman, President, Chief Executive Officer & Director
• Robert Polke, Global Head-Operations
• Mark Bradley, Chief Financial Officer & Executive Vice President
• Ruth Thorpe, Chief Information Officer
• Susan Williamson, Chief Compliance Officer & Senior Vice President

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among Endo International's employees.

Who are some of Endo International's key competitors?

Some companies that are related to Endo International include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR) and Supernus Pharmaceuticals (SUPN).
View all of ENDP's competitors.

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.65%), LSV Asset Management (1.03%), Bank of New York Mellon Corp (0.93%), Balyasny Asset Management LLC (0.00%), Balyasny Asset Management LLC (0.00%) and Bain Capital Public Equity Management II LLC (0.00%). Company insiders that own Endo International stock include International Plc Endo and Shane Cooke.
View institutional ownership trends for Endo International.

Which institutional investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Geode Capital Management LLC, Marshall Wace LLP, New York State Common Retirement Fund, Tudor Investment Corp Et Al, Hunter Associates Investment Management LLC, O Shaughnessy Asset Management LLC, and Hennion & Walsh Asset Management Inc..
View insider buying and selling activity for Endo International or view top insider-selling stocks.

Which institutional investors are buying Endo International stock?

ENDP stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, Bain Capital Public Equity Management II LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Citadel Advisors LLC, BNP Paribas Arbitrage SA, Jane Street Group LLC, and Caption Management LLC.
View insider buying and selling activity for Endo International or or view top insider-buying stocks.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $5.24.

How much money does Endo International make?

Endo International has a market capitalization of $1.22 billion and generates $2.90 billion in revenue each year. The company earns $183.94 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does Endo International have?

Endo International employs 3,397 workers across the globe.

When was Endo International founded?

Endo International was founded in 1997.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

Where are Endo International's headquarters?

Endo International is headquartered at First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at (531) 268-2000, via email at [email protected], or via fax at 800-329-3636.